Lexeo Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
LXEO$3.14+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $35,014 | $121,466 |
| Investments | 86,504 | - |
| Prepaid expenses and other current assets | 4,603 | 2,828 |
| Total current assets | 126,121 | 124,294 |
| Restricted cash | 3,252 | 3,252 |
| Investments | 7,012 | - |
| Property and equipment, net | 1,028 | 1,056 |
| Lease right-of-use assets - finance, net | 1,460 | 1,763 |
| Lease right-of-use assets - operating | 8,069 | 9,442 |
| Total assets | $146,942 | $139,807 |
| Liabilities and Stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $6,417 | $3,794 |
| Accrued expenses and other current liabilities | 13,759 | 10,840 |
| Current portion of lease liabilities - finance | 570 | 518 |
| Current portion of lease liabilities - operating | 2,100 | 2,087 |
| Total current liabilities | 22,846 | 17,239 |
| Non-current liabilities | ||
| Non-current portion of lease liabilities - finance | 817 | 1,247 |
| Non-current portion of lease liabilities - operating | 6,437 | 7,786 |
| Total liabilities | 30,100 | 26,272 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024; 500,000,000 shares authorized as of December 31, 2023; 26,668,485 shares issued and 26,646,378 shares outstanding as of December 31, 2023 | 3 | 3 |
| Treasury stock, at cost, 3,827 common shares at December 31, 2024 and 0 common shares at December 31, 2023 | (17) | - |
| Additional paid-in capital | 397,132 | 295,372 |
| Accumulated other comprehensive loss | (103) | - |
| Accumulated deficit | (280,173) | (181,840) |
| Total stockholders' equity | 116,842 | 113,535 |
| Total liabilities and stockholders' equity | $146,942 | $139,807 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.